AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 222 min read$MEDP

Medpace 3Q 2026: Revenue $716M, EPS $4.84— 10-Q Summary

Medpace Holdings reported Q3 2026 revenue of $716M, up 8.5% YoY, with net income rising 23.7% to $137.46M and EPS increasing 25.4% to $4.84. Growth was driven by Metabolic, Oncology, and CNS services. Nine-month revenue grew 16.9%, net awards reached $873.4M, and backlog increased 5.6% YoY to $3.17B. The company plans organic growth and selective acquisitions.

Original reporting
tradingview.com
Published Oct 22, 2026, 8:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 8:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Medpace 3Q 2026: Revenue $716M, EPS $4.84— 10-Q Summary — source image
Source · tradingview.com
Decision brief

The 30-second read

$MEDPBullishMed
01

Why it matters

The earnings release provides fresh data on revenue growth and profitability, offering traders a basis for short‑term positioning.

02

Market read

Earnings beat may trigger buying pressure in MEDP and related CRO stocks.

03

What to watch

Backlog growth of 5.6% and potential bolt‑on acquisitions could drive longer‑term upside.

Relevance 8/10Novelty 8/10Timing: after-hours release on Oct 22

Background

Medpace is a mid‑cap contract research organization that provides clinical trial services across multiple therapeutic areas.

Company-level read

Ticker impact

$MEDPBullishHigh confidence
Context

Medpace Holdings reported Q3 2026 revenue of $716M, up 8.5% YoY, and EPS of $4.84, marking the first public disclosure of these results.

Expected impact

likely modest upside as the market prices in the earnings beat and revenue growth

Evidence & confidence

The company posted better-than-expected earnings and double‑digit revenue growth, which typically drives short‑term buying pressure.

Market effects

Sector

Strong CRO earnings may boost sentiment toward contract research organizations and biotech services.

Regional

U.S. biotech and pharma service stocks could see modest gains.

Global

Limited to the CRO sector; no broad market impact.

Counterpoint

What could challenge this read

If expectations were already high, the modest beat may not sustain price gains.

Key entities

  • Company
    Medpace Holdings

    Contract research organization (CRO) reporting Q3 2026 results.

Read at source← All news

StoryMedpace Reports Q3 Earnings Beat and Authorizes $1 Billion Buyback

Also covered by

4 outlets

Related articles

OCT 23
$MEDPMedAI 8/10

MEDP Q3 deep dive: bookings strength drives growth, margin expansion continues

MEDP reported Q3 revenue of $716M, beating estimates, with EPS of $4.84 and adjusted EBITDA of $172.1M. The company reconfirmed full-year revenue guidance of $2.85B and raised EPS guidance to $18.15. Growth was driven by strong bookings in oncology research and margin expansion from a favorable project mix. Management highlighted stable competition, low turnover, and sustained bookings momentum, but noted project cancellations as a watchpoint.

finance.yahoo.com2 min
OCT 22
$MEDPHighAI 8/10

Medpace (MEDP) Q3 2026 Earnings Call Transcript

Medpace (MEDP) reported Q3 2026 revenue of $716M, up 8.5% YoY, with EBITDA of $172.1M (up 16%) and net income of $137.5M (up 23.7%). Guidance raised: revenue $2.835B-$2.855B (12-12.8% growth), EBITDA $638M-$652M (14.4-16.9% growth), EPS $17.97-$18.32. Board approved $1B share repurchase program. Net new business awards up 10.6% QoQ.

finance.yahoo.com2 min
OCT 22
$MEDPMed

Medpace Q3 Earnings Call Highlights

Medpace reported a 10.6% year-over-year increase in net new business awards to $873.4 million in Q3, with a total 12-month backlog of $3.02 billion. Ending backlog was $3.2 billion, up 5.6% year-over-year. The company expects $1.99 billion of backlog to convert into revenue over the next year. Management noted shifts in therapeutic mix and strong pending opportunities. Medpace plans to provide 2027 guidance in February, with fourth-quarter awards and cancellations influencing the outlook.

finance.yahoo.com2 min
OCT 22
$MEDPHighAI 8/10

Medpace Q3 2026 slides: record awards fuel profit beat, guidance raised

Medpace Holdings (NASDAQ:MEDP) reported Q3 2026 revenue of $716.0M, up 8.5% YoY, and adjusted earnings of $4.84 per share, exceeding estimates. Net income rose 23.7% to $137.5M, with EBITDA margin widening to 24.0%. The company raised its full-year guidance, citing record new business awards and strong profitability trends. Shares traded near $659.37, close to their 52-week high.

investing.com2 min
OCT 22
$MEDPHighAI 8/10

Why is Medpace stock sliding today?

Medpace Holdings Inc (MEDP) fell 1.6% in after-hours trading after its Q3 2026 earnings report. Adjusted EPS of $4.84 beat estimates, but full-year revenue guidance of $2.835B-$2.855B missed expectations. The board replaced a $527M stock buyback program with a $1B program. Insiders sold $467M in shares over the past year. The S&P 500, Dow Jones, and NASDAQ also declined during regular trading.

investing.com2 min